Read this how some parasite infect do not get resolved.
KPU/HPU: A MAJOR PIECE OF THE PUZZLE IN OVERCOMING CHRONIC LYME DISEASE
May 1, 2010 in Science/Research by Scott Forsgren
Dr. Dietrich Klinghardt MD, PhD is a practicing physician in Kirkland, Washington with a focus on the treatment of chronic neurological conditions such as Lyme disease, autism, and CFIDS. In the many years that he has treated patients with chronic infections, he has observed that, for many, recovery is elusive. Patients may often plateau or find that their recovery is stalled. In other cases, patients may not succeed in their attempts to rid the body of a particular toxic or infectious burden; such as in patients with long-standing or therapy-resistant late stage Lyme disease.
In looking for possible explanations as to why some patients struggle more than others to regain their health, Dr. Klinghardt has found a high correlation between patients with chronic Lyme disease and those with Kryptopyrroluria (KPU), or more precisely Hemopyrrollactamuria (HPU). The condition is alternatively known as the "Mauve Factor" or "Malvaria". HPU may be an inherited condition but it can also be induced by childhood psychological trauma or chronic infections.
The HPU complex is a biochemical marker and neurotoxic substance frequently identified in the urine of patients with autism, learning disabilities, alcoholism, substance abuse, schizophrenia, ADHD, Down syndrome, depression, bipolar disorders, and even criminal behavior. Some estimate the incidence of KPU to be 40-70% in schizophrenia; 50% in autism; 30% in ADHD; and 40-80% in alcoholism and substance abuse.
Dr. Klinghardt has found the incidence of HPU in Lyme disease to be 80% or higher; in patients with heavy metal toxicity (lead, mercury, cadmium, and others) over 75%; and in children with autism over 80%. These are very significant percentages of the patient population with chronic illness that may benefit from a treatment program which addresses HPU. Normal, healthy controls do not test positive for HPU.
In 1958, a psychiatric research program in Saskatchewan, Canada led by Abram Hoffer MD, PhD, the father of orthomolecular psychiatry, was looking for the possible biochemical origin of schizophrenia. One study involved evaluating the urine for certain chemical fractions and evaluating those of schizophrenic patients and those of normal controls. The effort yielded the "mauve factor" - a specific substance that reliably allowed the examiners to identify the schizophrenic patients, as it was not identified in the normal controls.
Early on, the substance was known as "the mauve factor" due to the mauve color that was observed on the stained paper. It was then termed "kryptopyrrole", later identified as hydroxy-hemopyrrolin-2-one (HPL). The researchers first called the disease associated with this condition "Malvaria", but it was renamed by Dr. Carl Pfeiffer MD, PhD to "Pyrolleuria" which was, for no obvious reason, consistently spelled "Pyrroluria" in later publications. In the 1970's, Dr. Pfeiffer created an assay for the condition and was able to show clinical improvement in positive patients with high doses of zinc and vitamin B6.
Elevated levels of HPL found in urine are the result of an abnormality in heme synthesis. Hemoglobin is the substance the holds iron in the red blood cells. HPL is a byproduct of hemoglobin - or heme - synthesis and can be identified in the urine. HPLs bind to zinc, biotin, manganese, vitamin B6, arachidonic acid and other important compounds and lead to a significant depletion of these substances in the body.
Turning to the importance of zinc, biotin, manganese, vitamin B6, and arachidonic acid in the body, it becomes clear how widespread the problem may be that is created by this condition.
Zinc deficiency may result in emotional disorders, delayed puberty, rough skin, delayed wound healing, growth retardation, hypogonadism, hypochlorhydria, mental lethargy, short stature, diarrhea, stretch marks or striae (which may be misinterpreted as Bartonella in some patients), white spots on the fingernails, reduction in collagen, macular degeneration, dandruff, skin lesions such as acne, hyperactivity, loss of appetite, reduced fertility, transverse lines on the fingernails, defective mineralization of bone leading to osteoporosis and many others.
Zinc is a powerful anti-oxidant and lower levels of zinc, as found in those with HPU, lead to an increase in oxidative stress. Lower levels of zinc are correlated with low levels of glutathione, an important part of the detoxification system. Zinc is required to support proper immune function. "White blood cells without zinc are like an army without bullets," says Dr. Klinghardt.
Biotin deficiency may be evidenced by rashes, dry skin, Seborrheic Dermatitis , brittle nails, fine or brittle hair, and hair loss. More importantly, however, it may be associated with depression, lethargy, hearing loss, fungal infections, muscle pain, and abnormal skin sensations such as tingling. Biotin is an important factor in the production of energy in the mitochondria. Biotin is essential for a healthy brain and nervous system. Biotin deficiency is associated with many aspects of the aging process.
Manganese deficiency may be associated with joint pain, inflammation, and arthritis. It may result in a change in hair pigment or a slowing of hair growth. It is essential for normal growth, glucose utilization, lipid metabolism, and production of thyroid hormone. It may be associated with diseases such as diabetes, Parkinson's disease, osteoporosis, and epilepsy.
Vitamin B6 deficiency is thought to be a rare occurrence. However, in those with HPU, this is not the case. B6 deficiency may lead to nervousness, insomnia, irritability, muscle weakness, poor absorption of nutrients, decrease of key enzymes and cofactors involved in amino acid metabolism, impairment in the synthesis of neurotransmitters, impairment in the synthesis of hemoglobin, seborrhoeic dermatological eruptions, confusion, and neuropathy. Similar to zinc, B6 is also an anti-oxidant and correlates to levels of glutathione.
Arachidonic acid (from omega-6) deficiency may lead to the impairment of white blood cell function, primarily the leukocytes which may lead to one being more vulnerable to infection. It may lead to neuropathy, neural and vascular complications in preterm babies, skin eruptions, behavior changes, sterility in males, arthritic conditions, dry eyes, growth retardation, dry skin and hair, slow wound healing, hair loss, kidney dysfunction, heart beat abnormalities, and miscarriages.
When one considers the magnitude of potential health problems that may be present when a single condition causes a deficiency in zinc, biotin, manganese, vitamin B6, and arachidonic acid simultaneously, the negative implications on health are almost endless.
HPU and Lyme Disease
Three possible origins of HPU are discussed in the literature: genetics, early childhood trauma, and chronic infections. The connection between HPU and many of the illnesses previously discussed has been known for quite some time. However, never before has a connection been observed or published between HPU and Lyme disease. This discovery has been a key for Dr. Klinghardt to return his patients to a better state of health and wellness. The changes he has observed have been profound.
Dr. Klinghardt has found that 4 of 5 patients with chronic Lyme disease test highly positive for this condition. That suggests that 80% of patients with symptoms of chronic Lyme disease might benefit from a treatment protocol that addresses HPU.
Dr. Klinghardt believes that it is not possible to have chronic symptomatic Lyme disease as an adult without a preceding mold illness or the patient having developed HPU. He postulates that the biotoxins from microbes block one or more of the eight enzymes of heme synthesis. This leads to a significant loss of key minerals in white blood cells which effectively disarms cellular immunity.
One young adult female struggling with Lyme for several years had severe multiple chemical sensitivities (MCS) that were not improved by any previous treatment. After starting the HPU protocol, she noticed improvements in her MCS for the first time since she became ill. Other patients with intractable chronic infections have experienced significant improvements in immune function and a resulting lowering of total microbial body burden.
Dr. Klinghardt has observed numerous patients that have struggled to rid the body of parasitic infestations. In these patients, regardless of the interventions used, the patient continues to expel these parasites on an ongoing basis. Therapy-resistant infections are a hallmark sign of HPU. Dr. Klinghardt has found that once the HPU protocol is put in place, there is often swift resolution of long-standing infections and infestations. This includes patients who have failed years of Antibiotic therapy for chronic or late stage Lyme disease.